ERG Holding Company, LLC

ERG Holding Company, LLC is a clinical research organization that specializes in conducting trials across various medical conditions, supporting advancements in healthcare through research collaboration. Founded in 2014 by Vikash Malasi, ERG Holding Company, LLC conducts clinical research aimed at understanding and treating various health conditions. The company has undergone a significant change in ownership when it was acquired by Linden from DFW Capital Partners in May 2018. The firm is headquartered in the United States, with operations across states such as Texas, Florida, New York, and Ohio.

It has participated in 2 funding rounds, with the most recent deal taking place in May 2018. ERG Holding Company, LLC offers clinical research services across a range of health conditions including psychiatric disorders, pain management, and Alzheimer’s disease. Their services cater to pharmaceutical and biotechnology companies, facilitating the development of new diagnostics and treatments through participant engagement in trials. With a focus on diverse geographical markets, they conduct both outpatient and inpatient studies, contributing valuable insights into health issues.

The revenue of ERG Holding Company, LLC is primarily generated through partnerships with pharmaceutical and research sponsors who fund clinical trials. The company is compensated for various services, including participant recruitment and data analysis. Additionally, revenue is enhanced through participation fees from subjects enrolled in studies targeting prevalent health conditions, operating within a B2B framework. Moving forward, ERG Holding Company, LLC aims to leverage the acquisition by Linden to bolster organic growth and explore strategic acquisitions.

Although specific upcoming products or services have not been disclosed, the company is poised to expand its reach within existing markets while considering new geographical regions to enhance its service offerings. The acquisition will provide the necessary resources to support these growth initiatives, enabling ERG to further contribute to advancements in medical research.